Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Drug Hunter - drug discovery, distilled
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares ...
Tersolisib (STX-478) | PI3Kα Inhibitor | MedChemExpress
STX-478|CAS |DC Chemicals
STX-478
Tersolisib (STX-478) | PI3Kα Inhibitor | CAS 2883540-92-7 | Selleck ...
STX-478 | PI3Kα inhibitor | TargetMol
Tersolisib (STX-478) | PI3Kα H1047R inhibitor | Probechem Biochemicals
RCSB PDB - 8TDU: STX-478, a Mutant-Selective, Allosteric Inhibitor ...
礼来为何 25 亿美元收购 PI3Kα 抑制剂 STX-478？ - 知乎
The first-in-human trial of STX-478, a mutant-selective PI3Kα inhibitor ...
First-in-Human study of STX-478, a mutant-selective PI3Kalpha inhibitor ...
Abstract PS7-02: First-in-human results of STX-478, a mutant-selective ...
Eli Lilly to Acquire Scorpion Therapeutics’ PI3Kα Inhibitor STX-478 for ...
Phase I/II trial STX-478, a mutant-selective PI3Kα inhibitor, in ...
STX-478 Yields Efficacy, Tolerability in PI3K-Mutated Advanced Solid Tumors
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 ...
Novel PI3Kα Inhibitor STX-478 Offers Precise Treatment and Reduced ...
(PDF) STX-478, a Mutant-Selective, Allosteric PI3Ka Inhibitor Spares ...
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka ...
Abstract P4-07-04: STX-478, a mutant-selective PI3Kα H1047X inhibitor ...
Free energy landscape of the PI3Kα C-terminal activation ...
Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities ...
Relay Therapeutics - best in class PI3Kα抑制剂？ Relaytherapeutics成立于2015年 ...
(STX-478) - 药物靶点：PI3Kα_在研适应症：晚期恶性实体瘤，乳腺癌，女性生殖器官肿瘤_专利_临床_研发
Targeting PIK3CA alteration STX-478 monotherapy good ORR compared to ...
PI3K-α抑制剂：Relay Therapeutics 凭借 RLY-2608 设定了高标准。STX-478 能否打败RLY-2608 ...
関西医科大学附属病院 新薬開発科 | 進行固形腫瘍患者を対象に変異選択的PI3Kα阻害薬STX-478の単剤療法及び他の抗悪性腫瘍薬との併用 ...
STX-478(STX-478) - 药物靶点：PIK3CA H1047X_在研适应症：晚期恶性实体瘤，女性生殖器官肿瘤，HR阳性乳腺癌_专利 ...
Cancer Discovery丨突变型特异的PI3Kα变构抑制剂STX-478展现良好的抗肿瘤效果且无代谢功能异常医药新闻-ByDrug-一 ...
STX-478: A New Drug for HR+/HER2- Breast Cancer | Chris De Savi posted ...
Mutant-selective PI3Kα inhibitor STX-478 trial results
Lilly Acquires Scorpion Therapeutics, Breast Cancer Treatment ...
Tersolisib (STX-478) | PI3K 抑制剂 | 现货供应 | 美国品牌 | 免费采购电话400-668-6834
HR陽性HER2陰性乳癌を含む固形癌にPI3Kα阻害薬STX-478は優れた忍容性と有望な効果【SABCS 2024】：日経メディカル
Tersolisib (STX-478) | PI3Kα抑制剂 | MCE
There are a few exciting updates on PI3K Inhibitors! Following the ...
STX478 Datasheet(PDF) - Suntsu Electronics, Inc.
Exciting news from our portfolio company, Scorpion Therapeutics! Eli ...
Abstract PO1-20-04: STX-478-101: A phase 1/2, first-in-human study of ...
In silico discovery of a novel potential allosteric PI3Kα inhibitor ...
美国新药STX-478治疗晚期实体瘤，展现出良好的疗效和安全性-出国看病-盛诺一家
PI3K-产品分类-Felix
2025，第一个起飞的重磅炸弹
Eli Lilly’s Groundbreaking Study on STX-478: A New Hope for Advanced ...
ACS Fall 2023首次披露，追踪国际首创进展-美迪西生物医药
#stx478 #pi3kα #lilly #scorpiontherapeutics | Giuseppe Giannini
【審査番号2491】【STX-478】進行固形腫瘍患者を対象に、変異選択的PI3Kα阻害薬STX-478の単剤療法及び他の抗悪性腫瘍薬との併用 ...
Lilly社、米Scorpion社買収で変異選択的PI3Kα阻害薬のSTX-478を獲得：日経バイオテクONLINE
ESMO 2025: A phase I/II trial of LY4064809 (STX-478), a pan-mutant ...
STX-478, a best-in-class, mutant-selective, allosteric inhibitor of ...
